Skip to content

Author

C. Reduzzi

We have 3 of 191 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Implementing liquid biopsy in HR+/HER2- metastatic breast cancer: challenges and opportunities.

PURPOSE OF REVIEW Liquid biopsy (LB) is rapidly transforming the management of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC). In this review, we discuss the most recent findings on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), exploring their roles across the tre...

V. Frescura, M. Cristofanilli, C. Reduzzi et al. · 0 citations
Review Aug 2026

Inflammatory breast cancer: improving research and care through the integration of preclinical evidence and technological advances.

A comprehensive overview of current knowledge on its applications in IBC is provided, highlighting the potential of circulating biomarkers to enhance disease characterization, diagnosis, risk assessment, and personalized treatment and the promising role of artificial intelligence in improving diagnostic accuracy.

E. Nicolò, M. Manai, Amr S. Soliman et al. · 1 citation
Review Open access Jul 2026

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

Evidence supporting ctDNA for early response monitoring during neoadjuvant therapy, postoperative minimal residual disease detection, and longitudinal molecular surveillance is summarized and ctDNA‐guided therapeutic interception strategies and emerging multimodal cell‐free DNA approaches are discussed.

S. Di Cosimo, V. Appierto, C. Reduzzi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.